Molecular basis of human gamma-globin gene activation.

Information

  • Research Project
  • 6921322
  • ApplicationId
    6921322
  • Core Project Number
    R01HL073455
  • Full Project Number
    5R01HL073455-03
  • Serial Number
    73455
  • FOA Number
    RFA-HL-02-15
  • Sub Project Id
  • Project Start Date
    7/25/2003 - 20 years ago
  • Project End Date
    6/30/2007 - 16 years ago
  • Program Officer Name
    EVANS, GREGORY
  • Budget Start Date
    7/1/2005 - 18 years ago
  • Budget End Date
    6/30/2006 - 17 years ago
  • Fiscal Year
    2005
  • Support Year
    3
  • Suffix
  • Award Notice Date
    9/9/2005 - 18 years ago

Molecular basis of human gamma-globin gene activation.

DESCRIPTION (provided by applicant): The long-term objective of the research is to develop reagents that activate human gamma globin gene transcription in the adult for treatment of beta-thalassemia and sickle cell anemia. It is known that expression of the fetal gamma globin genes greatly ameliorates the effects of these diseases, however it is not known how the human gamma globin genes are normally suppressed (or expressed at very low levels) when the expression of the human gamma globin genes switches to that of the delta and beta globin genes. It could be the result of an absence of transcription factors required for gamma globin gene expression or the presence of active suppressors of gamma globin expression or both. The aim of this application is therefore twofold: the characterization of the stage specific factors that are required for gamma globin gene expression and/or the stage specific factors that suppress gamma globin gene expression. Two independent in vivo approaches will be used. One uses chromatin precipitation to directly purify and sequence the proteins bound to the gamma globin gene promoters in the fetal stage and adult stage. The other is a functional assay to obtain single chain antibodies that switch on the gamma globin genes in the adult stage.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    216000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
    NHLBI:216000\
  • Funding Mechanism
  • Study Section
    ZHL1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ERASMUS MEDICAL CENTER
  • Organization Department
  • Organization DUNS
    411761687
  • Organization City
    ROTTERDAM
  • Organization State
  • Organization Country
    NETHERLANDS
  • Organization Zip Code
    3015 GE
  • Organization District
    NETHERLANDS